AlphaTON Capital receives public congratulations from Nasdaq for innovative approach to funding cancer research through asset tokenization, displayed on Nasdaq Tower in Times Square. Partnership with Cyncado Therapeutics revolutionizes cancer research funding by leveraging blockchain technology and asset tokenization, connecting global investors directly with promising oncology research programs. This collaboration addresses critical challenges in cancer research funding by providing enhanced liquidity, transparent allocation, reduced barriers, and accelerated timelines. Cyncado Therapeutics developing next-generation cancer treatments targeting previously undruggable tumor pathways through this innovative funding approach. Nasdaq Tower feature signals growing institutional acceptance of tokenized assets in regulated markets. Future plans include expanding tokenization initiative to additional therapeutic areas and research institutions.

Read more at GlobeNewswire: AlphaTON Capital Receives Nasdaq Congratulations for